HC Wainwright Comments on ProKidney FY2025 Earnings

ProKidney Corp. (NASDAQ:PROK) – Analysts at HC Wainwright issued their FY2025 earnings estimates for shares of ProKidney in a research report issued to clients and investors on Tuesday, December 16th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.53) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for ProKidney’s Q4 2025 earnings at ($0.15) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.62) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at ($0.31) EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ProKidney in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.40.

ProKidney Stock Performance

NASDAQ:PROK opened at $2.35 on Thursday. ProKidney has a fifty-two week low of $0.46 and a fifty-two week high of $7.13. The company has a 50 day moving average price of $2.63 and a 200 day moving average price of $2.37. The stock has a market capitalization of $706.95 million, a P/E ratio of -4.27 and a beta of 1.79.

ProKidney (NASDAQ:PROK) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.04 million.

Insiders Place Their Bets

In other ProKidney news, Director Brian Jg Pereira sold 502,136 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $2.37, for a total transaction of $1,190,062.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 41.49% of the stock is currently owned by insiders.

Institutional Trading of ProKidney

Hedge funds have recently modified their holdings of the stock. Zullo Investment Group Inc. purchased a new position in ProKidney in the third quarter valued at $28,000. AQR Capital Management LLC raised its position in ProKidney by 106.4% in the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after purchasing an additional 27,098 shares in the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in shares of ProKidney in the 2nd quarter valued at about $36,000. Jefferies Financial Group Inc. acquired a new position in shares of ProKidney during the third quarter worth about $158,000. Finally, Virtu Financial LLC purchased a new stake in shares of ProKidney during the third quarter worth approximately $203,000. 51.59% of the stock is currently owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.